Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05636397
Other study ID # 1000077413
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2023
Est. completion date March 2028

Study information

Verified date November 2023
Source The Hospital for Sick Children
Contact Rachana Patel, MSc, CCRP
Phone +1(416)-813-7654
Email rachana.patel@sickkids.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and explore the PK/PD of L-CIT supplementation in preterm infants to prevent the development of inflammatory pathways initiated by low levels of plasma CIT, specifically in preterm infants with post surgical NEC and BPD±PH.


Description:

Preterm infants are born with underdeveloped organs and immune systems, placing them at great risk for morbidity. They are more susceptible to inflammatory injury, particularly from conditions of prematurity mediated by inflammatory pathways such as bronchopulmonary dysplasia (BPD) and necrotizing enterocolitis (NEC). L-CIT, an amino acid, is the first intermediate in the urea cycle as well as a precursor to arginine and nitric oxide (NO), which promotes blood flow. It is made in the intestine and has been shown to exert vasoprotective and anti-inflammatory effects. BPD-PH and NEC are two specific inflammatory diseases of prematurity involving CIT, arginine or NO deficiencies. Evaluation of the safety and PK/PD of L-CIT supplementation for diseases involving CIT, arginine or NO deficiencies in preterm infants is important. Therefore, in this trial the investigator would like to evaluate the safety and pharmacokinetics/pharmacodynamics (PD) of L-CIT supplementation in preterm infants post surgical NEC and BPD-PH.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 2028
Est. primary completion date December 2027
Accepts healthy volunteers No
Gender All
Age group 1 Month to 6 Months
Eligibility Arm 1: BPD±PH: Inclusion Criteria: - Born = 30 weeks at birth - Post-menstrual age (PMA) = 34 weeks - Echocardiographic evidence of PH for infants with BPD+PH - On invasive or non-invasive ventilation with RSS >2.0 for >12hours/day for at least 48 hours - Informed written consent (parents/substitute decision maker) Exclusion Criteria: - Congenital Heart Disease [Exceptions: small atrial septal defect (ASD), small ventricular septal defect (VSD), small patent ductus arteriosus (PDA)] - Infants with pulmonary vein stenosis - Concurrent sepsis with hemodynamic instability - Infants considered likely to die within next 7 days - Any other condition that, in the opinion of the investigator, may adversely affect the infant's ability to complete the study or its measures or pose significant risk to the infant. Arm 2: surgical NEC Inclusion Criteria - Born = 30 weeks at birth - Recovering from Stage IIIb NEC as per modified Bell's staging (pneumoperitoneum requiring surgery) - Tolerating 30 ml/kg/day of enteral feeds - On invasive or non-invasive ventilation (NIPPV/nCPAP) with RSS >2.0 for > 12hours/day for at least 48 hours, 10-14 days post surgery - Informed written consent (parents/substitute decision maker) - Considered medically stable by clinical team Exclusion Criteria: - Congenital heart disease (except small ASD, small VSD and non hsPDA) - Pulmonary vein stenosis - Concurrent sepsis with hemodynamic instability - Likely to die within next 7 days - Other condition significantly affecting pulmonary function independent of prematurity or NEC

Study Design


Intervention

Dietary Supplement:
L-Citrulline
Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).

Locations

Country Name City State
Canada The Hospital For Sick Children Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
The Hospital for Sick Children

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of oral L-Citrulline administration The number of patients with adverse events (AE) as a measure of safety and tolerability 5 years
Secondary Association of blood pressure as one of the PD outcomes with maximum L-CIT concentration (Cmax) Blood pressure of the study participants will be associated with PK measures of L-CIT exposure i.e. Cmax using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies. 5 years
Secondary Association of stoma or nasogastric output as one of the PD outcomes with maximum L-CIT concentration (Cmax) Stoma or nasogastric output of the study participants will be associated with PK measures of L-CIT exposure i.e. Cmax using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies. 5 years
Secondary Association of stool output as one of the PD outcomes with maximum L-CIT concentration (Cmax) Stool output from the study participants will be associated with PK measures of L-CIT exposure i.e. Cmax using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies. 5 years
Secondary Association of blood pressure with the area under the concentration time curve (AUC) for L-CIT Blood pressure of the study participants will be associated with PK measures of L-CIT exposure i.e. Area under Concentration time curve (AUC) using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. 5 years
Secondary Association of stoma or nasogastric output with the area under the concentration time curve (AUC) for L-CIT Stoma or nasogastric output of the study participants will be associated with PK measures of L-CIT exposure i.e. Area under Concentration time curve (AUC) using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. 5 years
Secondary Association of stool output with the area under the concentration time curve (AUC) for L-CIT Stool output from the study participants will be associated with PK measures of L-CIT exposure i.e. Area under Concentration time curve (AUC) using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. 5 years
Secondary Association of blood pressure with minimum L-CIT concentration (Cmin) Blood pressure of study participants will be associated with PK measures of L-CIT exposure i.e. Cmin using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies. 5 years
Secondary Association of stoma or nasogastric output with minimum L-CIT concentration (Cmin) Stoma or nasogastric output from study participants will be associated with PK measures of L-CIT exposure i.e. Cmin using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies. 5 years
Secondary Association of stool output with minimum L-CIT concentration (Cmin) Stool output from study participants will be associated with PK measures of L-CIT exposure i.e. Cmin using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies. 5 years
Secondary Correlation between CIT and arginine levels Correlation between changes in CIT and arginine levels with nitrite/nitrate levels 5 years
Secondary Biomarkers of inflammation The levels of IL-1ß, IL-6, IL-8, IL-10, TNFa will be measured in tracheal aspirates and blood plasma. The aggregated levels fo these cytokines will reflect the inflammatory status of the study participant. 5 years
Secondary Oxidative stress Oxidative stress (measured in tracheal aspirates and blood) 5 years
Secondary Respiratory Score (RSS) The respiratory severity score (RSS) is a simplified severity score consisting of the mean airway pressure (MAP) multiplied by the fraction of inspired oxygen (FiO2). This score ranges from 0 to 12, with a higher score indicating more severe lung disease. 5 years
Secondary Desaturation index The oxygen desaturation index (ODI) is commonly used to evaluate the severity of nocturnal hypoxemia. The ODI is defined as the number of episodes of oxygen desaturation per hour of sleep with desaturation events of >=10sec/ sampled hour. 5 years
Secondary Changes in Blood Pressure Changes in diastolic and systolic blood pressure prior to and during CIT treatment. 5 years
Secondary Stoma, nasogastric or stool output Volume of stoma, nasogastric or stool output prior to and during CIT treatment 5 years
Secondary Ventilation Days on mechanical ventilation, non-invasive ventilation, and supplementary oxygen 5 years
Secondary BPD severity Moderate to severe BPD based on the different mode of ventilatory support needed at 36 wks PMA.
No BPD = off all oxygen and positive pressure support Moderate BPD = low flow oxygen only Severe BPD= positive pressure support (high flow, CPAP, NIPPV, or ETT)
5 years
Secondary BPD number of days of survival free of BPD 5 years
Secondary Pre-discharge mortality Number of study participants who died during NICU admission. 5 years
Secondary Postnatal steroid Use Number of days study participants received postnatal steroids during their NICU stay. 5 years
Secondary Bayley's scale for infant development Bayley Scales of Infant and Toddler Development is an extensive formal developmental assessment tool for diagnosing developmental delays in early childhood. BSID is the commonly used abbreviation for Bayley Scales of Infant and Toddler Development. Bayley-III includes a motor score, and fine and gross motor subtest scores. The standardized mean motor score is 100 (SD 15), with scores lower than 85 indicating mild impairment, and lower than 70 indicating moderate or severe impairment.In this particular trial, the investigator would be looking at the correlation between the inflammatory markers (IL-1ß, IL-6, IL-8, IL-10, TNFa) and Neurodevelopmental outcomes from Bayley's scale during 18-24M follow up visit in babies received L-Citrulline during their NICU stay. 5 years
See also
  Status Clinical Trial Phase
Withdrawn NCT01950585 - Hydroxyurea in Pulmonary Arterial Hypertension Early Phase 1
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Completed NCT03649932 - Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing Phase 1
Recruiting NCT04554160 - Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT01894035 - Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
Not yet recruiting NCT04083729 - Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy N/A
Completed NCT02821156 - Study on the Use of Inhaled NO (iNO) N/A
Completed NCT02216279 - Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension Phase 2
Terminated NCT02246348 - Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) N/A
Terminated NCT02243111 - Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound N/A
Recruiting NCT01913847 - Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension Phase 3
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT06240871 - Contrast Enhanced PA Pressure Measurements
Completed NCT02377934 - Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
Recruiting NCT01091012 - Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension Phase 3
Completed NCT02275793 - The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
Completed NCT00739375 - The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension. Phase 1
Completed NCT01463514 - Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension N/A
Completed NCT01484899 - Smoking: a Risk Factor for Pulmonary Arterial Hypertension? N/A